ARTICLE | Product Development
Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI
February 28, 2020 1:46 AM UTC
Updated on Feb 28, 2020 at 1:51 AM UTC
Migraine drug marks Biohaven’s first FDA approval
Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval. NURTEC ODT, a CGRP antagonist, is formulated as a quick-dissolving tablet. Biohaven gained $2.63 to $43.45 in after-hours trading...